Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Dissecting PTPN7‐driven aggressiveness in IDH‐wildtype astrocytomas: multi‐omics, clinical validation, and spatial transcriptomics for prognostic insights

Open access
Liu, Tung, Lin, Yu-Chieh, Chang, Pei-Chi, Hueng, Dueng-Yuan, Li, Yao-Feng · 2025 · Discover Oncology

Abstract

BACKGROUND: Gliomas, particularly IDH-wildtype astrocytomas, remain highly aggressive and resistant to current therapies. Despite advances in molecular classification, effective therapeutic targets are still limited. Consequently, identifying new targets is essential to improve patient survival. PTPN7, a tyrosine phosphatase implicated in MAPK signaling, is known to play roles in various malignancies but remains underexplored in gliomas. This study examines the prognostic significance, spatial distribution, and immune-related functions of PTPN7, aiming to elucidate its potential as a prognostic role and therapeutic target in glioma treatment. MATERIALS AND METHODS: We analyzed PTPN7 mRNA expression in gliomas via TCGA, CGGA, and single-cell RNA sequencing (GSE131928 and GSE89567). Kaplan determined prognostic significance-Meier and uni-/multi-variate Cox survival analyses. Gene set enrichment analysis (GSEA) was used to identify dysregulated pathways, immune signatures, and cell-type enrichments. We also applied CIBERSORT to evaluate the relationships between PTPN7 expression and 12-principal cell states and 22 immune populations. Spatial transcriptomics (Ivy Glioblastoma Atlas, 10 × Genomics Visium) mapped PTPN7 distribution; these findings were corroborated by immunohistochemistry-validated protein expression in 70 cases. RESULTS: Pan-cancer analysis revealed PTPN7 overexpression in multiple malignancies, including glioma. Notably, PTPN7 was significantly elevated in IDH-wildtype astrocytomas, correlating with higher tumor grades and poorer overall survival. GSEA indicated that high PTPN7 is linked to T-cell differentiation, macrophage/monocyte activation, and dendritic cell-associated pathways. Both immune deconvolution and single-cell analyses showed that PTPN7 positively correlates with myeloid series and T-cell populations, supported by additional GSEA findings. In the Ivy dataset and spatial transcriptomics, PTPN7 was concentrated in peri-necrotic, cellular tumor, and slightly lower in the infiltrating border regions, consistent with immune interaction sites. Immunohistochemical data further demonstrated high PTPN7 expression tracks with increased tumor grade, reaching statistical significance in IDH-wildtype astrocytomas and confirming its clinical relevance. CONCLUSION: This study positions PTPN7 as a prognostic biomarker and immune modulator in gliomas, particularly IDH-wildtype astrocytomas. Its expression correlates with tumor aggressiveness and immune infiltration, potentially driving glioma progression. Targeting PTPN7 may disrupt immune evasion and support tumor eradication, indicating a promising therapeutic avenue in immunotherapy-based strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12672-025-02662-5

Cites

Statistics

Figures

Fig. 1 Pan‐cancer analysis of PTPN7 in tumor versus normal across multiple cancer types. A Each box represents the 25th–75th percentiles, with the median indicated by a horizontal line, with dots showing data spread. Significance levels (*p < 0.05, **p < 0.01, ***p < 0.001) are noted above each comparison. B To the right, an inset compares GBM (n = 153, red) and LGG (n = 516, red) to normal brain samples (n = 5, blue), highlighting marked PTPN7 upregulation in gliomas, particularly in GBM. C Summary statistics (N, mean, SD, and 95% CI) of PTPN7 TPM by WHO grade and subtype (oligodendroglioma, IDH‐mutant astrocytoma, IDH‐wildtype astrocytoma). D–F Box plots showing PTPN7 distribution split by molecular subgroup within each WHO grade
Fig. 1 Pan‐cancer analysis of PTPN7 in tumor versus normal across multiple cancer types. A Each box represents the 25th–75th percentiles, with the median indicated by a horizontal line, with dots showing data spread. Significance levels (*p < 0.05, **p < 0.01, ***p < 0.001) are noted above each comparison. B To the right, an inset compares GBM (n = 153, red) and LGG (n = 516, red) to normal brain samples (n = 5, blue), highlighting marked PTPN7 upregulation in gliomas, particularly in GBM. C Summary statistics (N, mean, SD, and 95% CI) of PTPN7 TPM by WHO grade and subtype (oligodendroglioma, IDH‐mutant astrocytoma, IDH‐wildtype astrocytoma). D–F Box plots showing PTPN7 distribution split by molecular subgroup within each WHO gradeCC BY-NC-ND · PubMed Central
Fig. 2 PTPN7 expression, survival analysis, and grade correlation in gliomas. A–D Box plots contrasting normal (blue) vs. tumor (pink) PTPN7 expression for pan-gliomas, IDH‐wildtype astrocytoma, IDH‐mutant astrocytoma, and oligodendroglioma. E–H Kaplan–Meier curves categorize patients into High (pink) vs. Low (blue) PTPN7 groups, demonstrating worse survival in High expression. I–L After adjusting for clinical covariates, Cox survival analyses identified PTPN7 as a potential prognostic factor in pan-gliomas, IDH‐wildtype astrocytoma, and oligodendroglioma. M–P Box plots illustrate that PTPN7 increases with advancing glioma grade (M–O) or remains unchanged in oligodendroglioma (P)
Fig. 2 PTPN7 expression, survival analysis, and grade correlation in gliomas. A–D Box plots contrasting normal (blue) vs. tumor (pink) PTPN7 expression for pan-gliomas, IDH‐wildtype astrocytoma, IDH‐mutant astrocytoma, and oligodendroglioma. E–H Kaplan–Meier curves categorize patients into High (pink) vs. Low (blue) PTPN7 groups, demonstrating worse survival in High expression. I–L After adjusting for clinical covariates, Cox survival analyses identified PTPN7 as a potential prognostic factor in pan-gliomas, IDH‐wildtype astrocytoma, and oligodendroglioma. M–P Box plots illustrate that PTPN7 increases with advancing glioma grade (M–O) or remains unchanged in oligodendroglioma (P)CC BY-NC-ND · PubMed Central
Fig. 3 The meta-analysis, Nomogram, and Drivers of PTPN7 Expression. A A forest plot summarizing hazard ratios (HR) for high PTPN7 expression across the CGGA and TCGA glioma cohorts shows that elevated PTPN7 predicts poorer survival (common‐effect HR = 1.30, 95% CI 1.16–1.46, p < 0.001). B A nomogram incorporating PTPN7 expression, age, Karnofsky performance score, tumor grade, and treatments assign points to each factor. Higher total points reflect a worse prognosis, and the lower axis indicates corresponding survival probabilities at 1, 3, and 5 years. C Analysis of PTPN7 mutations in 690 glioma samples identified only three cases. D–E No recurrent driver mutations were detected across all glioma subtypes
Fig. 3 The meta-analysis, Nomogram, and Drivers of PTPN7 Expression. A A forest plot summarizing hazard ratios (HR) for high PTPN7 expression across the CGGA and TCGA glioma cohorts shows that elevated PTPN7 predicts poorer survival (common‐effect HR = 1.30, 95% CI 1.16–1.46, p < 0.001). B A nomogram incorporating PTPN7 expression, age, Karnofsky performance score, tumor grade, and treatments assign points to each factor. Higher total points reflect a worse prognosis, and the lower axis indicates corresponding survival probabilities at 1, 3, and 5 years. C Analysis of PTPN7 mutations in 690 glioma samples identified only three cases. D–E No recurrent driver mutations were detected across all glioma subtypesCC BY-NC-ND · PubMed Central
Fig. 4 GSEA results for PTPN7 in three glioma subtypes. A IDH‐wildtype astrocytoma, B IDH‐mutant astrocytoma, and C oligodendroglioma. Each color traces the running enrichment score of a hallmark gene set (listed at the top). Higher curves indicate stronger enrichment in tumors with high PTPN7. D A Venn diagram highlights 14 hallmark sets shared across the three subtypes, underscoring a common immunoinflammatory profile (red text) link with high PTPN7 in gliomas. E Venn diagram illustrating immune gene set (C7) overlaps among IDH‐wildtype (yellow), IDH‐mutant (blue), and oligodendroglioma (pink). Colored numbers highlight T‐cell (red), macrophage/monocyte (blue), and dendritic cell (green) subsets across 3-glioma subtypes
Fig. 4 GSEA results for PTPN7 in three glioma subtypes. A IDH‐wildtype astrocytoma, B IDH‐mutant astrocytoma, and C oligodendroglioma. Each color traces the running enrichment score of a hallmark gene set (listed at the top). Higher curves indicate stronger enrichment in tumors with high PTPN7. D A Venn diagram highlights 14 hallmark sets shared across the three subtypes, underscoring a common immunoinflammatory profile (red text) link with high PTPN7 in gliomas. E Venn diagram illustrating immune gene set (C7) overlaps among IDH‐wildtype (yellow), IDH‐mutant (blue), and oligodendroglioma (pink). Colored numbers highlight T‐cell (red), macrophage/monocyte (blue), and dendritic cell (green) subsets across 3-glioma subtypesCC BY-NC-ND · PubMed Central
Fig. 5 Immunohistochemical quantification of PTPN7 in normal brain and gliomas. A TCGA proteomic analysis confirmed elevated PTPN7 expression in glioblastoma over normal tissue. B Summary table of PTPN7 density (mean ± SD) in normal tissue (n = 11) and IDH‐wildtype (n = 37) and IDH‐mutant glioma (n = 22). C Representative tissue cores (H&E, low‐power IHC, automated machine quantification, and high‐power IHC) reveal immunostaining ranging from 0.17 to 48.93. (Black = background [B], Blue = Tissue [T], Yellow “+” = staining cells). D, E Box plots of PTPN7 density by WHO grade for IDH‐wildtype or IDH‐mutant astrocytoma. F, G Comparisons of normal, low‐grade, and high‐grade groups. Elevated PTPN7 correlates with tumor grade in the IDH wildtype group but is obscure in the IDH mutant group
Fig. 5 Immunohistochemical quantification of PTPN7 in normal brain and gliomas. A TCGA proteomic analysis confirmed elevated PTPN7 expression in glioblastoma over normal tissue. B Summary table of PTPN7 density (mean ± SD) in normal tissue (n = 11) and IDH‐wildtype (n = 37) and IDH‐mutant glioma (n = 22). C Representative tissue cores (H&E, low‐power IHC, automated machine quantification, and high‐power IHC) reveal immunostaining ranging from 0.17 to 48.93. (Black = background [B], Blue = Tissue [T], Yellow “+” = staining cells). D, E Box plots of PTPN7 density by WHO grade for IDH‐wildtype or IDH‐mutant astrocytoma. F, G Comparisons of normal, low‐grade, and high‐grade groups. Elevated PTPN7 correlates with tumor grade in the IDH wildtype group but is obscure in the IDH mutant groupCC BY-NC-ND · PubMed Central
Fig. 6 Single‐Cell RNA-Seq Visualization of PTPN7 in IDH‐Wildtype (A–C) and IDH‐Mutant (E–G) Gliomas. UMAP plots (A, E) color-code cells by major lineage (tumor, T cell, glial, myeloid), while (B, F) display normalized PTPN7 expression (yellow = low, red = high). Violin plots (C, G) compare PTPN7 levels across lineages, showing significantly higher expression in T cells (blue) and myeloid cells (orange) (***p < 0.001). Arrows and arrowheads indicate clusters enriched for T or myeloid populations
Fig. 6 Single‐Cell RNA-Seq Visualization of PTPN7 in IDH‐Wildtype (A–C) and IDH‐Mutant (E–G) Gliomas. UMAP plots (A, E) color-code cells by major lineage (tumor, T cell, glial, myeloid), while (B, F) display normalized PTPN7 expression (yellow = low, red = high). Violin plots (C, G) compare PTPN7 levels across lineages, showing significantly higher expression in T cells (blue) and myeloid cells (orange) (***p < 0.001). Arrows and arrowheads indicate clusters enriched for T or myeloid populationsCC BY-NC-ND · PubMed Central
Fig. 7 Spatial Distribution of PTPN7 in Glioblastoma and Its Correlation with Cell Fractions. A Box plot of PTPN7 expression (y-axis) across five histologic regions (x-axis): leading edge (n = 19), infiltrating border (n = 24), cellular tumor (n = 30), microvascular proliferation (n = 25), and pseudopalisading cells around necrosis (n = 24). The results showed that PTPN7 is significantly elevated in the cellular tumor zone (p = 0.046) versus the leading edge. B Correlation table summarizing Spearman coefficients (and p-values) for PTPN7 expression across various tumor, stromal, and immune cell subsets in each region
Fig. 7 Spatial Distribution of PTPN7 in Glioblastoma and Its Correlation with Cell Fractions. A Box plot of PTPN7 expression (y-axis) across five histologic regions (x-axis): leading edge (n = 19), infiltrating border (n = 24), cellular tumor (n = 30), microvascular proliferation (n = 25), and pseudopalisading cells around necrosis (n = 24). The results showed that PTPN7 is significantly elevated in the cellular tumor zone (p = 0.046) versus the leading edge. B Correlation table summarizing Spearman coefficients (and p-values) for PTPN7 expression across various tumor, stromal, and immune cell subsets in each regionCC BY-NC-ND · PubMed Central
Fig. 8 Spatial transcriptomic profiling of an adult glioblastoma via the 10 × Genomics Visium platform. A H&E image showing the tissue section. B A pseudocolor map of the PTPN7 expression is overlaid in the same section. Key tumor subregions—leading edge, infiltrating border, cellular tumor, peri‐necrotic area, and necrotic core—are delineated by dashed lines
Fig. 8 Spatial transcriptomic profiling of an adult glioblastoma via the 10 × Genomics Visium platform. A H&E image showing the tissue section. B A pseudocolor map of the PTPN7 expression is overlaid in the same section. Key tumor subregions—leading edge, infiltrating border, cellular tumor, peri‐necrotic area, and necrotic core—are delineated by dashed linesCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists haven’t been fetched yet

References 40 · Cited by 4

Metadata

Authors
Liu, T., Lin, Y.-C., Chang, P.-C., Hueng, D.-Y., & Li, Y.-F.
Affiliations
  • Tri-Service General Hospital (TW)
  • Taoyuan Armed Forces General Hospital (TW)
  • National Defense Medical Center (TW)
Corresponding author
Li, Yao-Feng
Venue
Discover Oncology
Published
2025-05-24
Volume
16
Issue
1
Pages
914-914
ISSN
2730-6011 (ISSN-L)
OpenAlex
W4410708929
Cited by
4
References
40
Citations by year
2026: 2 · 2025: 2
FWCI
2.58
Type
journal article
Language
en
Open access
Licence
Locations
  • Discover Oncology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Tri-Service General Hospital (TSGH-E-111269)
  • National Science and Technology Council (113-2321-B-016 -005, 111-2314-B-016 -064 -MY3)
  • Taipei, Taichung, Kaohsiung Veterans General Hospital, Tri-Service General Hospital, Academia Sinica Joint Research Program (VTA113-T-4-2)
  • Ministry of National Defense Medical Affairs Bureau (MND-MAB-D-113167)
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
Keywords
glioma, protein tyrosine phosphatase, MAPK signaling, prognostic factors, therapeutic target, tumor immune microenvironment, myeloid cells, T cell differentiation, tumor grade, spatial transcriptomics, pan-cancer analysis, overall survival, tumor necrosis, tumor-infiltrating immune cells, cell of origin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dissecting PTPN7‐driven aggressiveness in IDH‐wildtype astrocytomas: multi‐omics, clinical validation, and spatial transcriptomics for prognostic insights. https://app.cochat.ai/papers/10.1007/s12672-025-02662-5
The paper
Liu, T., Lin, Y.-C., Chang, P.-C., Hueng, D.-Y., & Li, Y.-F. (2025). Dissecting PTPN7‐driven aggressiveness in IDH‐wildtype astrocytomas: multi‐omics, clinical validation, and spatial transcriptomics for prognostic insights. Discover Oncology. https://doi.org/10.1007/s12672-025-02662-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.